- Home
- INVX vs GERN Comparison
INVX vs GERN Comparison
Compare INVX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVX
- GERN
- Stock Information
- Founded
- INVX 2024
- GERN 1990
- Country
- INVX United States
- GERN United States
- Employees
- INVX N/A
- GERN N/A
- Industry
- INVX
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- INVX
- GERN Health Care
- Exchange
- INVX NYSE
- GERN Nasdaq
- Market Cap
- INVX 1.2B
- GERN 974.5M
- IPO Year
- INVX N/A
- GERN 1996
- Fundamental
- Price
- INVX $17.54
- GERN $1.15
- Analyst Decision
- INVX Hold
- GERN Buy
- Analyst Count
- INVX 2
- GERN 8
- Target Price
- INVX $16.50
- GERN $3.71
- AVG Volume (30 Days)
- INVX 395.2K
- GERN 8.9M
- Earning Date
- INVX 08-11-2025
- GERN 08-06-2025
- Dividend Yield
- INVX N/A
- GERN N/A
- EPS Growth
- INVX 19.36
- GERN N/A
- EPS
- INVX 2.31
- GERN N/A
- Revenue
- INVX $773,221,000.00
- GERN $116,293,000.00
- Revenue This Year
- INVX $39.72
- GERN $161.44
- Revenue Next Year
- INVX $0.81
- GERN $53.06
- P/E Ratio
- INVX $7.30
- GERN N/A
- Revenue Growth
- INVX 42.69
- GERN 22264.04
- 52 Week Low
- INVX $11.93
- GERN $1.14
- 52 Week High
- INVX $19.42
- GERN $4.89
- Technical
- Relative Strength Index (RSI)
- INVX N/A
- GERN 34.61
- Support Level
- INVX N/A
- GERN $1.20
- Resistance Level
- INVX N/A
- GERN $1.37
- Average True Range (ATR)
- INVX 0.00
- GERN 0.09
- MACD
- INVX 0.00
- GERN -0.01
- Stochastic Oscillator
- INVX 0.00
- GERN 5.71
About INVX INNOVEX INTERNATIONAL INC
Innovex International Inc designs, manufactures, sells, and rents mission-critical engineered products to the oil and natural gas industry. Its products are Subsea, Surface Wellheads, Well Construction, Well Completion, Production Solutions, Fishing & Intervention. Its products support upstream onshore and offshore activities. The group's geographic regions are North America, Latin America, Middle East & Asia Pacific, and Europe & Africa.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.